BioScrip, Inc. (Nasdaq: BIOS) saw its shares make a solid gain on Tuesday after another analyst issued a positive rating on the stock. Stock investors purchased 6,210 put options on the stock. This represents an increase of 2,424% compared to the typical volume of 246 put options. The company’s stock has lost tens of billions of dollars in shareholder value since initial reports of massive data mishandling by research firm Cambridge Analytica.

For US and Canadian Stocks, the Overview page includes key statistics on the stock's fundamentals, with a link to see more. Market Cap: capitalization or market value of a stock is simply the market value of all outstanding shares. Zacks Investment Research downgraded shares of Evoke Pharma (NASDAQ:EVOK) from a strong-buy rating to a hold rating in a report issued on Wednesday, Zacks.com reports. According to Zacks, “Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. 10/17/2019 · Evoke Pharma (NASDAQ:EVOK) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Tuesday, Zacks.com reports. The brokerage currently has a $1.00 target price on the specialty pharmaceutical company’s stock. 1/5/2017 · Zacks Rank & Key Picks. Evoke currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Arena Pharmaceuticals, Inc. ARNA, Cambrex Corporation CBM and Kamada Ltd. KMDA. While Cambrex sports a Zacks Rank #1 (Strong Buy), Arena Pharma and Kamada carry a Zacks Rank #2 (Buy).

EVOK: Evoke Pharma, Inc. broker recommendation chart. Get the latest chart with broker recommendations from Zacks Investment Research.

5/8/2019 · Stocks That Warrant a Look. Here are a few health care stocks worth considering as our model shows that these have the right mix of elements to beat on earnings this time around. Adverum Biotechnologies, Inc. ADVM has a Zacks Rank of 3 and an Earnings ESP of +1.82%. You can see the complete list of today’s Zacks #1 Rank stocks here. 10/20/2019 · Zacks Investment Research cut shares of Evoke Pharma (NASDAQ:EVOK) from a buy rating to a hold rating in a research note released on Wednesday, Zacks.com reports. According to Zacks, “Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. 8/17/2018 · Zacks Rank & Key Picks. Evoke currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks from the pharma space are Illumina ILMN and Ligand Pharmaceuticals LGND. Both the stocks carry a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. Evoke Pharma (NASDAQ: EVOK) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers on Benzinga. Evoke Pharma, Inc. Stock Price, Chart, Latest News, Technical Indicator and other information 5/8/2019 · Investor focus will remain on Evoke Pharma, Inc.’s EVOK progress and issues related to its new drug application (NDA) filling for Gimoti to treat diabetic gastroparesis when it reports first-quarter 2019 earnings results.

7/19/2016 · Each of these stock sports a Zacks Rank #1 (Strong Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.

8/17/2018 · Zacks Rank & Key Picks. Evoke currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks from the pharma space are Illumina ILMN and Ligand Pharmaceuticals LGND. Both the stocks carry a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. Evoke Pharma (NASDAQ: EVOK) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers on Benzinga. Evoke Pharma, Inc. Stock Price, Chart, Latest News, Technical Indicator and other information 5/8/2019 · Investor focus will remain on Evoke Pharma, Inc.’s EVOK progress and issues related to its new drug application (NDA) filling for Gimoti to treat diabetic gastroparesis when it reports first-quarter 2019 earnings results. Stocks That Warrant a Look. Here are a few health care stocks worth considering as our model shows that these have the right mix of elements to beat on earnings this time around. Adverum Biotechnologies, Inc. (NASDAQ: ADVM) has a Zacks Rank of 3 and an Earnings ESP of +1.82%. You can see the complete list of today’s Zacks #1 Rank stocks here. 6/1/2019 · Wall Street brokerages expect that Evoke Pharma Inc (NASDAQ:EVOK) will announce ($0.12) earnings per share (EPS) for the current fiscal quarter, Zacks reports. 11/2/2019 · Interactive Chart for Evoke Pharma, Inc. (EVOK), analyze all the data with a huge range of indicators.

7/11/2016 · AMPHASTAR PHARM (AMPH): Free Stock Analysis Report. EVOKE PHARMA (EVOK): Free Stock Analysis Report. To read this article on Zacks.com click here. Zacks Investment Research. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

For stock investors, the falling rates environment is now favoring one particular sector: consumer staples. Coeur Mining Inc (NYSE:CDE) SVP Hans John Rasmussen sold 7,500 shares of the company’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $4.78, for a total value of $35,850.00. Zacks Investment Research currently has $63.00 target price on the stock. According to Zacks, “Edgewell Personal Care Co. manufactures and markets personal care products. The price of the stock has increased by 4.5% since.COO Ryan Wilson bought 6,000 shares of CCT stock on 03/08/2018 at the average price of $16.18. The brokerage currently has a “hold” rating on the stock. TD Securities’ price target points to a potential downside of 0.90% from the company’s current price.

10/25/2019 · Evoke Pharma (NASDAQ:EVOK) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports.

Evoke Pharma (EVOK) Given a $9.00 Price Target by HC Wainwright Analysts (americanbankingnews.com) Evoke Pharma (EVOK) Announces FDA Acceptance of Gimoti NDA (zacks.com) FDA to Review Gimoti for Diabetic Gastroparesis in Adult Women (empr… For stock investors, the falling rates environment is now favoring one particular sector: consumer staples. Coeur Mining Inc (NYSE:CDE) SVP Hans John Rasmussen sold 7,500 shares of the company’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $4.78, for a total value of $35,850.00. Zacks Investment Research currently has $63.00 target price on the stock. According to Zacks, “Edgewell Personal Care Co. manufactures and markets personal care products. The price of the stock has increased by 4.5% since.COO Ryan Wilson bought 6,000 shares of CCT stock on 03/08/2018 at the average price of $16.18. The brokerage currently has a “hold” rating on the stock. TD Securities’ price target points to a potential downside of 0.90% from the company’s current price.

Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. EVOK: Evoke Pharma, Inc. equity research. Get the latest equity research information from Zacks Investment Research. 10/17/2019 · Evoke Pharma (NASDAQ:EVOK) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. The firm currently has a $1.00 price objective on the specialty pharmaceutical company’s stock. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The Zacks Scorecard is a complimentary set of indicators to use alongside the Zacks Rank. It allows the investor to better focus on the stocks that are the best fit for his or her personal investment style. We produce five unique ratings, including the Zacks Style Score, which combines the individual style scores into 1 rating: